Amaury Daste

5PUBLICATIONS
37CO-AUTHORS
Molecular targetsHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Oct 01, 2026
Setanaxib Added to Pembrolizumab for Fibroblast-Rich, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: a Phase 2 Randomized Study.

|Apr 09, 2026
Phase 1b study of ABBV-368, tilsotolimod, budigalimab, and nab-paclitaxel in patients with recurrent/metastatic head and neck squamous cell carcinoma.

Amaury Daste, Xiuning Le, Amani Makkouk

|Dec 22, 2025
INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.

Danny Rischin, Aaron R Hansen, Ezra E W Cohen

|Dec 21, 2023
Immunotherapy for head and neck squamous cell carcinoma: current status and perspectives.

Amaury Daste, Mathieu Larroquette, Nyere Gibson

|Jun 03, 2021
Cetuximab combined with paclitaxel or paclitaxel alone for patients with recurrent or metastatic head and neck squamous cell carcinoma progressing after EXTREME.

Thomas Chevalier, Amaury Daste, Esmaa Saada-Bouzid

Pageof 1

Frequent Collaborators

2 joint publications

Kevin J Harrington

1 joint publications

Thomas Chevalier

1 joint publications

Florence Huguet

1 joint publications

Charlotte Domblides